BioSpace News Archive

Market players must invest in advanced technologies to enhance the usability and efficiency of IV infusion pumps. Reduction in medication error has significantly improved the patient outcome, strengthening the growth trajectory of next-generation IV infusion pumps market.

The ongoing transformation of veganism into a culture has highlighted plant-based diet as the newfound arena of palatability. Upfront endorsements by popular sports celebrities like William sisters and mike Tyson are further gravitating the masses towards veganism.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce today that it has chosen to appoint award winning Novotech as the contract research organization (“CRO”) for a planned physician initiated study of NP-120 (Ifenprodil) for COVID-19 infected patients in South Korea

Clinical trials to test drug remdesivir in hospitalized adults with pneumonia due to novel coronavirus

TSI Incorporated, designer and manufacturer of precision air particle measurement instruments, is working with healthcare organizations across the globe to enable the use of its technologies to ensure worker safety in the midst of the coronavirus, or COVID-19, pandemic.

Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a business update.

In an effort to quickly support fast-emerging public health needs and inequities resulting from the COVID-19 pandemic, the CARESTAR Foundation released a $100,000 grant to the Centers For Disease Control Foundation.

The Canadian Medical Association welcomes the Government of Canada’s decision to mobilize businesses and manufacturers to urgently produce personal protective equipment and other critical supplies needed to combat COVID-19.

The U.S. Food and Drug Administration (FDA) has issued a complete response letter for the supplemental New Drug Application (sNDA) of the investigational medicine empagliflozin 2.5 mg as an adjunct to insulin for adults with type 1 diabetes.

PRA Health Sciences announced today the commercial availability of the COVID-19 Monitoring Program, a mobile app-driven, tiered initiative that allows employers, payers, providers and health systems to track the health and wellbeing of individuals who may be asymptomatic, exposed or diagnosed with COVID-19 during the pandemic.